13. Please select the correct answer (five points): a. A CAR…
Question Answered step-by-step 13. Please select the correct answer (five points): a. A CAR… 13. Please select the correct answer (five points):a. A CAR combines: (i) antigen-binding domains, usually a single-chain variable fragment (scFv), derived from the variable domains of antibodies; (ii) signaling domains of the TCR complex (CD3zeta); and (iii) additional costimulatory domains from receptors such as CD28, 0X40, and CD137 b. A CAR combines: (i) peptide/MHC binding domains of the TCR; (ii) signaling domains of the TCR complex (CD3zeta); and (iii) additional costimulatory domains, but not antigen-binding domains, from immunoglobulin molecules. c. A CAR combines: (i) antigen-binding domains derived from the variable domains of antibodies and peptide/MHC binding domains of the TCR; (ii) signaling domains of the TCR complex (CD3zeta); and (iii) Fc receptor domains. 14. Please select the INCORRECT answer (five points):Conditioning chemotherapy must be administered prior to CAR T-cell therapy and allow for enhanced proliferation and function of CAR T-cells, maximizing treatment efficacy. Conditioning chemotherapy is not needed prior to CAR T-cell therapy. Conditioning chemotherapy, among other effects, eliminates/extensively reduces Treg cells prior to CAR T-cell therapy. Conditioning chemotherapy reduces the numbers of lymphoid and likely other hemopoietic cells infiltrating the tumor. 15. Please select the INCORRECT answer (five points):a. CAR therapy may cause prolonged toxicities because the engineered T-cells may persist in vivo and produce elevated levels of cytokines that may lead to cytokine release syndrome, also known in severe cases as cytokine storm.b. The apoptotic cell death of tumor cells caused by the CAR engineered T cells is primarily responsible for the cytokine release syndrome.c. Recognition of antigen expressed on tumor cells by the chimeric antigen receptor is critical for the production of cytokines in vivo. 16. Please select the INCORRECT answer (five points):a. B-cell aplasia is a typical side effect of treating B-cell malignancies with CAR T cells recognizing pan-B-cell differentiation antigens. The loss of B cells after CAR T cell therapy is largely managed by replacement therapy with intravenous immunoglobulin.b. CAR T cell therapy targeting pan-B-cell antigens, such as CD19, is effective treatment of B cell malignancies in most patients.c. Non-malignant B cells are only transiently affected by CAR T cell therapy targeting pan-B-cell antigens, such as CD19, and immunoglobulin levels are restored soon after the treatment is completed. Science Biology BIOL 476 Share QuestionEmailCopy link Comments (0)
